Companies Cryptocurrencies
Kezar Life Sciences Inc
Kezar Life Sciences Inc
Exchange: NasdaqGS
IPO Date: 21/06/2018
CEO: Mr. John Fowler
Biotechnology Healthcare 🔗
  • KZR
  • 8.92
  • 429879776
    market cap
  • -0.4300003
If you bought

shares of Kezar Life Sciences Inc (KZR) on
You would have made
Old Price $12 Current Price $12

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco, California. The company is headquartered in South San Francisco, California and currently employs 24 full-time employees. The firm is engaged in developing novel small molecule therapeutics to treat autoimmune disorders, cancer, and malignant diseases. Its therapies target protein homeostasis. Its lead development program is KZR-616. KZR-616 is a selective small molecule inhibitor of the immunoproteasome. Its second program focuses on small-molecule modulators of the protein secretion pathway. Its protein secretion program is focused on the areas of oncology, inflammation and immune-oncology.

Address: 4000 Shoreline Ct Ste 300 South San Francisco CALIFORNIA 94080

Stay updated.